RT @Susumu_Manabe: 透析患者へのTAVI.STSデータベースから3000例を抽出して非透析症例と比較.やっぱりややリスクは高いらしい.SAVRとの比較ではないので、有効性はなんとも言えないが、十分有力な選択肢になり得ることは示された. https://t.c…
@kaulcsmc @RichardWhitloc2 @EulertJ @KardiologieHH @kaschenke @cardiojaydoc02 @DFCapodanno @naderjo @lamelaspablo @luedike @PLooserMD @AndrewJSauer @JHMontfort10 @mmamas1973 @VerwerftJan Mortality was about 35% at 1 year in the TVT registry. But that was
@GilbertTangMD @djc795 @mirvatalasnag @bkolskk @fjsawaya @cardioPCImom @willsuh76 @AnkurKalraMD @mszerlip showed TAVR w ESRD had higher 1 yr mortality c/w non-ESRD pts. https://t.co/QlRTggOKwf Earlier analysis showed ESRD TAVR had worse outcomes but mortal
RT @renalpages: Patients undergoing #TAVR with #ESRD are at higher risk and had higher in-hospital mortality and bleeding https://t.co/5K…
Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease - ScienceDirect https://t.co/et8Zy5Fszq
RT @renalpages: Patients undergoing #TAVR with #ESRD are at higher risk and had higher in-hospital mortality and bleeding https://t.co/5K…
RT @renalpages: Patients undergoing #TAVR with #ESRD are at higher risk and had higher in-hospital mortality and bleeding https://t.co/5K…
Patients undergoing #TAVR with #ESRD are at higher risk and had higher in-hospital mortality and bleeding https://t.co/5KxveLjJP7
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @atmizu: 透析患者のTAVRの話題ですね。 さて、日本はどうなりますかね #CardioJapan https://t.co/nNogXTLiXi
透析患者のTAVRの話題ですね。 さて、日本はどうなりますかね #CardioJapan https://t.co/nNogXTLiXi
Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease. 0ne-Year Death 37% vs 18% in Non ESRD pts. @JPUsdin https://t.co/QV7ZLMJheh
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
RT @JACCJournals: What are the outcomes of #TAVR in patients with end-stage renal disease? https://t.co/rlPfzFWW3G #JACC https://t.co/VXqaE…
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
RT @JACCJournals: Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient p…
Time to exercise caution while performing #TAVR on end-stage renal disease patients? New #JACC study found this patient population experiences higher in-hospital mortality and bleeding. https://t.co/QzuMosFK4x https://t.co/PtdituM9Ic
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
RT @Cardiology: #TAVR patients with #ESRD on dialysis may have higher rates of 30-day and 1-year mortality than nondialysis patients, new #…
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
RT @JACCJournals: What are the outcomes of #TAVR in patients with end-stage renal disease? https://t.co/rlPfzFWW3G #JACC https://t.co/VXqaE…
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
RT @JACCJournals: What are the outcomes of #TAVR in patients with end-stage renal disease? https://t.co/rlPfzFWW3G #JACC https://t.co/VXqaE…
RT @JACCJournals: What are the outcomes of #TAVR in patients with end-stage renal disease? https://t.co/rlPfzFWW3G #JACC https://t.co/VXqaE…
What are the outcomes of #TAVR in patients with end-stage renal disease? https://t.co/rlPfzFWW3G #JACC https://t.co/VXqaELQF4y
RT @Cardiology: #TAVR patients with #ESRD on dialysis may have higher rates of 30-day and 1-year mortality than nondialysis patients, new #…
RT @Cardiology: #TAVR patients with #ESRD on dialysis may have higher rates of 30-day and 1-year mortality than nondialysis patients, new #…
RT @Cardiology: #TAVR patients with #ESRD on dialysis may have higher rates of 30-day and 1-year mortality than nondialysis patients, new #…
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
RT @Cardiology: #TAVR patients with #ESRD on dialysis may have higher rates of 30-day and 1-year mortality than nondialysis patients, new #…
RT @VictorDayan1: En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace…
En pacientes con IRC en dialisis la mortalidad al año luego de TAVI es del 37%. Pareceria que en este caso el tratar hace mas daño que no tratar. @jpcostabel @JACCJournals @AATSHQ @j_alvarezgarcia @DOCNUNEZ https://t.co/dFNnR1rv7b
#TAVR patients with #ESRD on dialysis may have higher rates of 30-day and 1-year mortality than nondialysis patients, new #NCDR study shows: https://t.co/GJnq606tWp #JACC @STS_CTsurgery https://t.co/ybs8lFuI2d
RT @GenNextMD: Hard choice for Critical AS patients with ESKD...Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Dis…
Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease | JACC: https://t.co/b7VudTRDTY
透析患者へのTAVI.STSデータベースから3000例を抽出して非透析症例と比較.やっぱりややリスクは高いらしい.SAVRとの比較ではないので、有効性はなんとも言えないが、十分有力な選択肢になり得ることは示された. https://t.co/3dAOVn0p7v
Hard choice for Critical AS patients with ESKD...Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease | JACC: Journal of the American College of Cardiology @JACCJournals https://t.co/0K5Kl7NZ09
Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease Friendly reminder: "Do No Harm" https://t.co/AH16wkGKW1 https://t.co/hrgbMOUN3J
まあ,そうだろうなあ…>Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease https://t.co/PrjSrDkzT5
RT @naderjo: Guarded results of #TAVR in Patients With End-Stage Renal Disease https://t.co/KehjlU76hr #Cardiology #CardioTwitter
Guarded results of #TAVR in Patients With End-Stage Renal Disease https://t.co/KehjlU76hr #Cardiology #CardioTwitter